Iran has started manufacturing of two types of drugs, IRIB News reported.
CEO of Iranian Pooyesh Darou company, Mijtaba Tabatabai, spoke briefly about the new drugs on the sidelines of the unveiling ceremony.
Pooyesh Darou is one of the most well established biotechnology companies in Iran and Middle East.
According to Tabatabai, the two drugs are Reteplase and Pegfilgrastim.
Reteplase is a thrombolytic drug, used to treat heart attacks by breaking up the clots that cause them.
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim, which serves to stimulate the level of white blood cells. Pegfilgrastim treatment can be used to stimulate the bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.
Tabatabai noted that Iran is second only country in the world that is able to manufacture Reteplase domestically, adding that until the end of 2013, Iran plans to start the mass production of the drug.
As for Pegfilgrastim, according to Tabatabai, this was being manufactured only by a Swiss company, however now Iran is also able to manufacture it domestically. He added that its price on the world market is about $1000, which is approximately 1.226 million rials, by official USD rate in Iran.
Tabatabai said that both drugs were positively tested on patients.